Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
NRXP
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.70
vs -1.40
Q4.23
N/A
-0.50
vs -1.50
Q1.24
N/A
-0.74
vs -1.30
Q2.24
N/A
-0.75
vs -1.20
Q3.24
N/A
-0.15
vs -0.70
Q4.24
N/A
-0.30
vs -0.50
Q1.25
N/A
-0.34
vs -0.74
Q2.25
N/A
NA
vs -0.75
Q3.25
+111%
0.02
vs -0.15
Q4.25
+125%
0.07
vs -0.30
Sales Growth
YoY
Current
Estimates
Q3.23
NA
NA vs NA
Q4.23
NA
8K vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-50%
4K vs 8K
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Q3.25
NA
7.4M vs NA
Q4.25
+258233%
10.3M vs 4K
Return on Equity
QoQ
Q1.23
+3887%
38.87
vs -1.38
Q2.23
+310%
3.1
vs 38.87
Q3.23
+98%
0.98
vs 3.1
Q4.23
+37%
0.37
vs 0.98
Q1.24
+43%
0.43
vs 0.37
Q2.24
+43%
0.43
vs 0.43
Q3.24
+9%
0.09
vs 0.43
Q4.24
+39%
0.39
vs 0.09
Q1.25
+22%
0.22
vs 0.39
Q2.25
+49%
0.49
vs 0.22
Institutionnal Ownership
QoQ
Q1.23
30
30
vs 35
-14%
Q2.23
34
34
vs 30
13%
Q3.23
36
36
vs 34
6%
Q4.23
33
33
vs 36
-8%
Q1.24
32
32
vs 33
-3%
Q2.24
21
21
vs 32
-34%
Q3.24
21
21
vs 21
NA
Q4.24
27
27
vs 21
29%
Q1.25
23
23
vs 27
-15%
Q2.25
23
23
vs 23
NA
seekingalpha.com
12 hours ago
Quote Panel
Key Metrics
Relative Strength
NRXP
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
2026-Revenue
199%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
BTIG
initialisePrevious: Not converted
2025-04-02
Now: Buy
EF Hutton
initialisePrevious: Not converted
2024-10-21
Now: Buy
H.C. Wainwright
initialisePrevious: Not converted
2022-06-30
Now: Buy
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.20Â ( 7.14%)
After-hours 2.92$
-0.08 (-2.67%)
Relative Strenght
50
Volume Buzz
104%
Earning Acce
No
Dist 52w H.
50%